Try our Advanced Search for more refined results
January 17, 2022
AOP Orphan Pharmaceuticals GMBH v. Pharmaessentia USA Corporation
Case Number:
1:22-mc-91022
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
February 16, 2022
Austrian Pharma Co.'s €142M Award Nixed In Germany
A German court has set aside a €142 million ($161.8 million) damages award issued to Austrian pharmaceutical company AOP Orphan in the midst of a contentious dispute with Taiwanese drug developer PharmaEssentia Corp. over an ill-fated deal to develop a new blood cancer treatment.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login